Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.
Saved in:
| Title: | Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. |
|---|---|
| Authors: | van der Straten L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. l.vanderstraten@iknl.nl.; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. l.vanderstraten@iknl.nl.; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands. l.vanderstraten@iknl.nl., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Dinnessen MAW; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Visser O; Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Posthuma EFM; Department of Internal Medicine, Reinier The Graaf Hospital, Delft, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Doorduijn JK; Erasmus MC Cancer Institute, Department of Hematology, University Medical Center Rotterdam, Rotterdam, The Netherlands., Langerak AW; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands., Kater AP; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands., Dinmohamed AG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Erasmus MC, Department of Public Health, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands. |
| Source: | Blood cancer journal [Blood Cancer J] 2023 Jan 13; Vol. 13 (1), pp. 15. Date of Electronic Publication: 2023 Jan 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36635262 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22van+der+Straten+L%22">van der Straten L</searchLink>; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. l.vanderstraten@iknl.nl.; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. l.vanderstraten@iknl.nl.; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands. l.vanderstraten@iknl.nl.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dinnessen+MAW%22">Dinnessen MAW</searchLink>; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Visser+O%22">Visser O</searchLink>; Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Posthuma+EFM%22">Posthuma EFM</searchLink>; Department of Internal Medicine, Reinier The Graaf Hospital, Delft, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Doorduijn+JK%22">Doorduijn JK</searchLink>; Erasmus MC Cancer Institute, Department of Hematology, University Medical Center Rotterdam, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Langerak+AW%22">Langerak AW</searchLink>; Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dinmohamed+AG%22">Dinmohamed AG</searchLink>; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands.; Erasmus MC, Department of Public Health, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2023 Jan 13; Vol. 13 (1), pp. 15. <i>Date of Electronic Publication: </i>2023 Jan 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36635262 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-023-00784-z Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 15 Titles: – TitleFull: Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: van der Straten L – PersonEntity: Name: NameFull: Levin MD – PersonEntity: Name: NameFull: Dinnessen MAW – PersonEntity: Name: NameFull: Visser O – PersonEntity: Name: NameFull: Posthuma EFM – PersonEntity: Name: NameFull: Doorduijn JK – PersonEntity: Name: NameFull: Langerak AW – PersonEntity: Name: NameFull: Kater AP – PersonEntity: Name: NameFull: Dinmohamed AG IsPartOfRelationships: – BibEntity: Dates: – D: 13 M: 01 Text: 2023 Jan 13 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2044-5385 Numbering: – Type: volume Value: 13 – Type: issue Value: 1 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |